Tyrosine Kinase Inhibitors (TKIs) are a class of targeted therapies designed to block the activity of specific tyrosine kinases involved in cancer cell signaling. By inhibiting these kinases, TKIs disrupt critical pathways responsible for tumor cell proliferation, survival, angiogenesis, and metastasis. TKIs are widely used in the treatment of various cancers, including lung cancer, chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and breast cancer, among others.
Types of TKIs
- Small-Molecule TKIs: These drugs are designed to target intracellular kinases by penetrating the cell membrane. They typically target mutated or overactive kinases that drive cancer progression.
- Monoclonal Antibodies: These are larger molecules that target extracellular regions of tyrosine kinase receptors on cancer cells, preventing activation of the receptor.
Clinical Points for Oncology Pharmacists:
- Resistance: Tumors can develop resistance to TKIs through secondary mutations (e.g., T790M in EGFR), amplification of alternative signaling pathways, or alterations in drug transport.
- Side Effects: Common side effects include diarrhea, rash, hepatotoxicity, fatigue, and QT prolongation. Managing these adverse effects is crucial to maintaining patient quality of life.
- Monitoring: Routine monitoring of liver enzymes, electrolytes, and ECG (for QT prolongation) is often required during TKI therapy.
- Drug Interactions: TKIs often interact with CYP450 enzymes, leading to potential drug-drug interactions. Oncology pharmacists must review patients’ medication lists carefully.
Table: Comparison of Different Types of Tyrosine Kinase Inhibitors
| TKI | Target Kinase(s) | Indications | Common Adverse Effects | Resistance Mechanisms | Monitoring | Notable Drug Interactions |
|---|---|---|---|---|---|---|
| Imatinib (Gleevec) | BCR-ABL (CML), KIT (GIST), PDGFR | Chronic Myelogenous Leukemia (CML), GIST, Ph+ ALL | Fluid retention, myelosuppression, rash, GI upset | BCR-ABL mutations, amplification of KIT/PDGFR | CBC, liver function, renal function, ECG (QT) | CYP3A4 substrate, strong inhibitors/inducers |
| Erlotinib (Tarceva) | EGFR (mutations, amplification) | Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer | Rash, diarrhea, fatigue, interstitial lung disease | EGFR T790M mutation, MET amplification | Liver function, ECG (QT), lung function | CYP3A4 substrate, strong inhibitors/inducers |
| Gefitinib (Iressa) | EGFR (mutations) | NSCLC (EGFR mutations) | Rash, diarrhea, hepatotoxicity, interstitial lung disease | EGFR T790M mutation | Liver function, ECG (QT), lung function | CYP3A4 substrate, strong inhibitors/inducers |
| Dasatinib (Sprycel) | BCR-ABL, SRC family kinases, KIT, PDGFR | CML, Ph+ ALL, Philadelphia chromosome-positive leukemia | Pleural effusion, bleeding, QT prolongation, myelosuppression | BCR-ABL mutations, SRC amplification | CBC, liver function, ECG (QT) | CYP3A4 substrate, strong inhibitors/inducers |
| Sunitinib (Sutent) | KIT, PDGFR, VEGFR | GIST, Renal Cell Carcinoma (RCC), Pancreatic NETs | Fatigue, diarrhea, hypertension, hand-foot syndrome | VEGFR, KIT mutations, resistance to PDGFR inhibition | CBC, liver function, blood pressure | CYP3A4 substrate, moderate inhibitors/inducers |
| Lapatinib (Tykerb) | HER2, EGFR | HER2-positive Breast Cancer (in combo with capecitabine) | Diarrhea, hepatotoxicity, rash, QT prolongation | HER2 mutations, altered EGFR expression | Liver function, ECG (QT) | CYP3A4 substrate, moderate inhibitors/inducers |
| Crizotinib (Xalkori) | ALK, ROS1, MET | ALK-positive NSCLC, ROS1-positive NSCLC | Visual disturbances, GI toxicity, hepatotoxicity | ALK gene rearrangement mutations | Liver function, vision, ECG (QT) | CYP3A4 substrate, strong inhibitors/inducers |
| Axitinib (Inlyta) | VEGFR, PDGFR, KIT | RCC (advanced/metastatic) | Hypertension, fatigue, diarrhea, hand-foot syndrome | VEGFR mutations, resistance to tyrosine kinase inhibition | Blood pressure, liver function | CYP3A4 substrate, moderate inhibitors/inducers |
|
Diarrhea, rash, interstitial lung disease |
Liver function, ECG (QT) |
CYP3A4 substrate, moderate inhibitors/inducers |
Important Clinical Points:
- Mechanism of Action: TKIs inhibit specific kinases, blocking downstream signaling pathways crucial for tumor growth.
- Adverse Effects: Most TKIs cause skin rash, gastrointestinal issues, and hepatotoxicity. Pulmonary toxicity (e.g., interstitial lung disease) can be a serious concern, particularly for EGFR inhibitors.
- Resistance: Resistance mechanisms often involve mutations in the target kinase (e.g., EGFR T790M) or activation of bypass pathways (e.g., MET amplification).
- Drug Interactions: Many TKIs are metabolized by the CYP3A4 enzyme, so interactions with CYP3A4 inhibitors or inducers can affect drug levels. These need to be closely monitored to ensure proper dosing and efficacy.